Navigation Links
Proteolix Announces the Appointment of John Scarlett, M.D., President and CEO
Date:2/25/2009

SOUTH SAN FRANCISCO, Calif., Feb. 25 /PRNewswire/ -- Proteolix, Inc., a leader in the discovery and development of novel therapeutics that target protein degradation pathways in cancer and autoimmune diseases, today announced the appointment of John A. Scarlett, M.D., to the position of President and Chief Executive Officer. Dr. Scarlett brings nearly 30 years of experience in drug development and commercialization to his new role. Susan Molineaux, Ph.D., who founded Proteolix in 2003, will transition from her position as Chief Executive Officer to serve as the company's Chief Scientific Officer.

"I am pleased to join the outstanding team at Proteolix, whose efforts have resulted in the discovery of the company's lead anticancer product, the proteasome inhibitor carfilzomib, for the treatment of multiple myeloma and other cancers," said Dr. Scarlett. "In particular, I am excited by the opportunity to oversee the advancement of carfilzomib, which has shown compelling single agent activity in several Phase 2 trials in multiple myeloma, through the final stages of clinical testing and into commercialization."

"I welcome Dr. Scarlett, whose extensive clinical and commercial experience will serve as an important asset to the company as carfilzomib advances through late-stage trials," stated Dr. Molineaux. "Proteolix has been successful in discovering and developing several inhibitors that selectively target the proteasome in new ways, which has allowed us to develop effective therapies for the treatment of both cancer and autoimmune diseases. I am proud of the progress our team has achieved to date and look forward to our continued successes."

On behalf of the Company's Board of Directors, Chairman Paul Hastings commented, "Proteolix has made remarkable strides under the leadership of Susan Molineaux in taking carfilzomib all the way from discovery through to successful Phase 2 clinical trials in a short period of time. As carfilzomib enters the next stage of clinical development, Dr. Scarlett's expertise and experience will be a highly valued addition to the Proteolix leadership team."

Dr. Scarlett most recently served as the Chief Executive Officer of Tercica, Inc., a publicly-traded biotechnology company, which he co-founded in 2002. While there, he led the company through the approval and commercialization of Increlex(R) and the commercialization of Somatuline Depot(R). Tercica merged in late 2008 with Ipsen, S.A. From 1993 through 2001, Dr. Scarlett served as Chief Executive Officer of Sensus Drug Development Corporation, where he led the development and commercialization of the endocrine product Somavert(R). Sensus was acquired by Pharmacia in 2001. Previously, he co-founded Covance Biotechnology Services, Inc., a contract recombinant protein manufacturing company, and was head of the North American Clinical Development Organization at Novo Nordisk Pharmaceuticals. He also held senior management positions at Greenwich Pharmaceuticals and McNeil Pharmaceuticals, a Johnson & Johnson company. Dr. Scarlett graduated with honors from the University of Chicago's Pritzker School of Medicine. He trained in internal medicine at the Hospital of the University of Pennsylvania, and in endocrinology and metabolism at the University of Colorado.

About Proteolix

Founded in December 2003, Proteolix, Inc. is a privately-held biopharmaceutical company, headquartered in South San Francisco, dedicated to discovering, developing and commercializing novel therapeutics that target protein degradation pathways for cancer and autoimmune diseases. Proteolix's lead product, carfilzomib, is the first in a new class of highly specific proteasome inhibitors, and is currently in multiple Phase 2 clinical studies to evaluate its safety and efficacy in hematologic and solid tumor malignancies. Proteolix is also developing a pipeline of novel proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor. For additional information on Proteolix, please visit www.proteolix.com.

    Contact information
    Investors:                             Media Inquiries:
    Matthew Ferguson                       BCC Partners
    Chief Financial Officer                Karen L. Bergman or Michelle Corral
    650-266-2825                           650-575-1509 or 415-794-8662
    investors@proteolix.com


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting
2. Proteolix Names Matthew Ferguson to Newly-Created Position of Chief Financial Officer
3. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
4. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
5. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
6. HEI, Inc. Announces Sale of RFID Division Assets
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
8. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
9. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
10. Brooke Franchise Corporation Announces Selected July Results
11. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... Leading pediatric oncology experts at Children’s National Health ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired ... Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... named one of Michigan’s 2017 Best and Brightest in Wellness® by Best and ... Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. ...
(Date:10/12/2017)... ... October 12, 2017 , ... In the United States, single-family ... some states—like New York, New Jersey, Massachusetts, Texas, Virginia, Connecticut, and California—the average ... extremely low property-tax rates, which contributes to the relatively lower cost of living ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Dining at the University of California Berkeley, and other leading institutions in announcing ... buying power of institutions to change the way animals are raised for food. ...
(Date:10/12/2017)... Antonio, Texas (PRWEB) , ... October 12, 2017 ... ... device and biologics manufacturer, has expanded its executive staff with the addition of ... , In this role, Slott will develop the national distribution and sales network, ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/19/2017)... 2017   ZirMed Inc ., a recognized leader in ... it has been ranked #1 by its users for the ... 2017 User Survey. ZirMed was recognized as the top-ranked end-to-end ... medical centers over 200 beds and holds one of the ... survey history. ...
(Date:9/12/2017)... Sept. 12, 2017  Consumer reviews on the independent review site ... the number one company for hearing aids, ranking it higher than ... brands. ... #1 by Consumers For Hearing Aids ... Hearing is an online store that provides high performance, state-of-the-art, German-engineered ...
Breaking Medicine Technology: